Kymera Therapeutics, Inc.
KYMR
$61.00
$1.111.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -75.91% | -48.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -75.91% | -48.07% | |||
| Cost of Revenue | -5.48% | -2.33% | |||
| Gross Profit | -6.60% | -15.06% | |||
| SG&A Expenses | -1.75% | 8.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.79% | -0.51% | |||
| Operating Income | -4.86% | -13.61% | |||
| Income Before Tax | -7.26% | -16.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.26% | -16.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.26% | -16.82% | |||
| EBIT | -4.86% | -13.61% | |||
| EBITDA | -3.18% | -14.91% | |||
| EPS Basic | 1.16% | -16.38% | |||
| Normalized Basic EPS | 5.80% | -16.39% | |||
| EPS Diluted | 1.16% | -16.38% | |||
| Normalized Diluted EPS | 5.80% | -16.39% | |||
| Average Basic Shares Outstanding | 8.52% | 0.38% | |||
| Average Diluted Shares Outstanding | 8.52% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||